TC BioPharm (Holdings) Ltd Stock Price, News & Analysis

TC Biopharm (NASDAQ: TCBP), a clinical-stage biotechnology company, will present at the LD Micro Invitational from June 7th to 9th, 2022, at Four Seasons Westlake Village. This prestigious 3-day investor event will feature around 200 companies, each presenting for 25 minutes followed by private meetings. TC Biopharm specializes in gamma-delta T cell therapies for cancer and viral infections, leading the way in clinical studies. Currently, the company is conducting pivotal trials for its OmnImmune® product in acute myeloid leukemia and ImmuniStim for Covid-19 treatment.

TC Biopharm (NASDAQ: TCBP) announced its participation in multiple upcoming conferences focused on allogeneic gamma-delta T cell therapies for cancer. Michael Leek, Co-founder and Executive Chairman, will present at the Allogeneic Cell Therapies Summit in Boston from May 9-11, and the Advanced Therapies Conference in London on May 24-25. Additionally, he will speak at the Next Generation CAR & T Cell Therapies 2022 in San Francisco from June 14-16, and the Onco Cell Therapy Summit in Boston from June 29-30. These events showcase TC Biopharm's innovative approaches in clinical-stage biopharmaceuticals.

On April 21, 2022, TC Biopharm (NASDAQ: TCBP) announced a donation to the Leukemia and Lymphoma Society to raise awareness for World AML Day. As a clinical-stage biotechnology company, TC Biopharm is developing gamma-delta T cell therapies for cancer and viral conditions, with ongoing phase 2b/3 trials for its OmnImmune® treatment targeting acute myeloid leukemia (AML). CEO Bryan Kobel emphasized the company's commitment to advancing novel cell therapies while collaborating with healthcare institutions.

TC BioPharm (NASDAQ: TCBP) has achieved a significant milestone by successfully registering the trademark 'CryoTC®', a proprietary freeze-thaw process for its lead oncology product, OmnImmune®. This innovative process enhances the product's accessibility and storage, establishing it as an 'off the shelf' cell therapy for potential treatments of acute myeloid leukemia and other cancers. With a strong clinical pipeline, TC BioPharm aims to lead in gamma-delta T cell therapies, combining innate and adaptive immune responses to tackle various cancers and viral infections.

TC Biopharm (NASDAQ: TCBP) has received equity research coverage from EF Hutton, which issued a 'Buy' rating with a target price of $5. This rating follows TC Biopharm's key milestones, including successful Phase 1b/2a trial results in late-stage Acute Myeloid Leukemia (AML) patients treated with allogeneic gamma-delta T cells and the granting of orphan drug status for its product OmnImmune® in AML. The company focuses on developing gamma-delta T cell therapies for cancer and has a robust pipeline and significant intellectual property portfolio.

TC Biopharm announced that it has received MHRA and Research Ethics Committee approvals to begin clinical trials for its OmnImmune® therapy to treat Acute Myeloid Leukemia (AML). The Phase 2/3 trials are set to start enrollment in the first half of 2022 in the UK, with plans to expand into the US afterward. Previously, OmnImmune® received orphan drug designation from the FDA. CEO Bryan Kobel expressed enthusiasm about progressing with their proprietary therapy following promising Phase 1b/2a results. The company is focused on developing gamma-delta T cell therapies with a strong pipeline for future indications.

On March 17, 2022, TC Biopharm (NASDAQ: TCBP) announced that the FDA granted orphan drug status to its lead product, OmnImmune®, for treating Acute Myeloid Leukemia (AML). This designation allows for a seven-year exclusive marketing period post-approval, enhancing commercial protection for OmnImmune®. The company aims to advance OmnImmune® through Phase 2b/3 trials, leveraging its innovative allogeneic gamma-delta T cell therapies. TC Biopharm positions itself at the forefront of cancer therapy development, with plans for enrollment in trials in both the UK and the US.

TC Biopharm (NASDAQ: TCBP) announced a significant enhancement of its intellectual property (IP) portfolio, which includes 6 granted patents and 45 pending applications related to gamma-delta T cell therapies. The IP covers revolutionary 'co-stimulatory' CAR-T cells aimed at lessening toxicity and expanding targeted therapy options. CEO Bryan Kobel emphasized the importance of this portfolio in establishing a competitive edge and advancing clinical development. The company continues to file additional applications, indicating a commitment to innovation in cancer and viral treatment therapies.

TC Biopharm announced positive interim results from its Phase 1a/2b study of TCB-002, OmnImmune®, targeting relapse/refractory Acute Myeloid Leukemia (AML). Out of 7 treated patients, 50% in the higher dose cohort achieved complete responses, with no serious safety concerns reported. The study evaluated safety and tolerability, indicating OmnImmune® is a promising therapeutic option for late-stage AML patients. The company plans to expand trials in 2022 and report further data, highlighting the potential of gamma-delta T cell therapies in treating blood cancers.